Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of karenitecin in treating patients who
have relapsed or refractory non-small cell lung cancer